ANA Pattern and Associated Rheumatic Diseases
| Homogenous (diffuse) | |
| • DNA-histone (nucleosome) | SLE, drug-induced LE, other diseases |
| • Mi-2 | Dermatomyositis (15%–20%) |
| Rim (peripheral) | |
| • dsDNA | SLE |
| Speckled | |
| • SS-A (Ro) | SLE, SCLE, primary Sjögren’s, systemic sclerosis, other diseases |
| • SS-B (La) | SLE, primary Sjögren’s, SCLE |
| • RNP | MCTD, systemic sclerosis, SLE |
| • Sm | SLE |
| • Ku | SLE, polymyositis/systemic sclerosis overlap |
| Nucleolar | |
| • Topoisomerase I (Scl-70) a | Systemic sclerosis (diffuse type) (20%–30%) |
| • RNAP III a | Systemic sclerosis (diffuse type) (4%–20%) |
| • Fibrillarin (U3-RNP) | Systemic sclerosis (diffuse type) (8%) |
| • TH/TO | Systemic sclerosis (limited type) (5%) |
| • PM- Scl (PM-1) | Polymyositis overlap (1%) |
| Centromere (kinetochore) | |
| • CENP | Limited scleroderma |
CENP, centromere protein; LE, lupus erythematosus; MCTD, mixed connective tissue disease; RNAP, RNA polymerase; RNP, ribonuclear protein; SCLE, subacute cutaneous lupus erythematosus; SLE, systemic lupus erythematosus; SS-A, Sjögren’s syndrome-related antigen A.
a Scl-70 & RNAP III have also been associated with a speckled pattern on indirect immunofluorescence.
